Idac-alpha: An alpha dosimetry software for normal organs and tissues

M. Andersson, A. Kluge, T. Meyer, E. Koumarianou, S. Mattsson

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review


Radiopharmaceuticals have been used for the treatment of various forms of cancer since the 1940s. In recent years, the advantages of alpha emitting radionuclides have emerged as a favourable treatment option. However, most alpha emitting radionuclides have long decay chains with long-lived daughter radionuclides. This leads to uncertainties in the dosimetry for normal organs and tissues, when established dosimetry models are employed. The aim of this project is to assign each progeny its own biokinetic behaviour. The novel dosimetry model was applied to 223Ra-dichloride, frequently used for the treatment of patients with metastatic bone disease from castration-resistant prostate cancer. In this dosimetry model, individual biokinetics for each daughter radionuclide was included. This resulted in a decrease in absorbed dose to bone surfaces and red marrow and increased absorbed dose to liver and kidney, when compared with dosimetry models assuming that the daughter nuclides follow the biokinetics of the parent radionuclide.

Sidor (från-till)327-333
Antal sidor7
TidskriftRadiation Protection Dosimetry
StatusPublished - 2021 okt. 1

Bibliografisk information

Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press. All rights reserved.

Ämnesklassifikation (UKÄ)

  • Radiologi och bildbehandling


Utforska forskningsämnen för ”Idac-alpha: An alpha dosimetry software for normal organs and tissues”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här